{"product_id":"dtil-bcg-matrix","title":"(DTIL) Precision BioSciences, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Precision BioSciences, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation decisions. The page already shows a real preview of the analysis, so you can review the actual content and format before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARCUS platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eARCUS is Precision BioSciences, Inc.'s core genome-editing engine, powering both in vivo and ex vivo programs and keeping the platform in the Star quadrant as the company scales. In 2025, its lead programs included PBGENE-HBV and PBGENE-DMD, while the gene-editing market was still growing at a double-digit pace. That mix of platform control and market growth makes ARCUS the company’s most strategic asset. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBGENE-HBV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBGENE-HBV is Precision BioSciences, Inc.'s lead in vivo gene-editing program for chronic hepatitis B, a disease that affects about 254 million people worldwide. Current antiviral care rarely clears infection, so the unmet need is large. If early clinical signals hold, this could be one of Precision BioSciences, Inc.'s highest-upside Stars in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences’ Servier alliance expands allogeneic CAR T work across multiple targets, strengthening the company’s cell-therapy pipeline. The partnership gives external validation in a market that is expected to exceed $10 billion by 2030, while also shifting some development burden to a larger pharma partner. It is one of Precision’s strongest commercial ties and a clear Stars asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eiECURE collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe iECURE deal pushes Precision BioSciences, Inc.’s ARCUS platform into gene-editing therapeutics beyond its wholly owned pipeline, so it widens reach without full balance-sheet risk. That fits a Star-style position: high growth, high strategic value, and a partner-backed path to broader clinical upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands ARCUS into a new therapeutic lane\u003c\/li\u003e\n\u003cli\u003eShares cost and development risk\u003c\/li\u003e\n\u003cli\u003eRaises platform validation with a partner\u003c\/li\u003e\n\u003cli\u003eSupports high-growth BCG positioning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Precision BioSciences, Inc., this is less about one asset and more about platform proof. The iECURE collaboration shows ARCUS can move into partnered gene-editing programs, which strengthens long-term optionality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIn vivo editing focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences’ in vivo editing push fits a fast-growing gene-editing market, with sector growth often modeled in the low double digits through 2030. By end-2025, the company had concentrated capital and talent on in vivo programs, giving it the profile of a rising core franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocused capital on in vivo programs\u003c\/li\u003e\n\u003cli\u003eAligned with faster-growing biotech demand\u003c\/li\u003e\n\u003cli\u003eRising core franchise profile by end-2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences’ ARCUS Star: High-Growth, Partner-Backed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc.’s Stars are ARCUS-led programs with clear growth optionality: PBGENE-HBV targets a 254 million-person chronic hepatitis B market, while the Servier alliance and iECURE deal extend ARCUS into partner-backed pipelines. By end-2025, the company had concentrated capital on in vivo editing, fitting a high-growth, high-value BCG Star profile.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eARCUS platform\u003c\/td\u003e\n\u003ctd\u003eCore engine\u003c\/td\u003e\n\u003ctd\u003eIn vivo + ex vivo use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGENE-HBV\u003c\/td\u003e\n\u003ctd\u003eHigh unmet need\u003c\/td\u003e\n\u003ctd\u003e254M chronic HBV cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServier alliance\u003c\/td\u003e\n\u003ctd\u003ePartner validation\u003c\/td\u003e\n\u003ctd\u003eAllogeneic CAR T expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003ePrecision BioSciences BCG Matrix maps its pipeline by growth and market share to spot Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean BCG Matrix for Precision BioSciences, Inc. to quickly spot growth, cash, and weak spots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Precision BioSciences, Inc. that boosts credibility and helps decision-makers validate key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences ended FY2025 with 0 approved commercial products, so it has no true Cash Cow in the BCG sense. The company stayed pre-revenue from marketed therapies, and cash generation still depended on external funding and collaboration inflows. Until an approved product launches, this segment remains a cost center, not a steady cash source.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 marketed therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences had 0 marketed therapies, so there was no mature product franchise to generate steady cash flow. In the latest reported period, the company remained precommercial, with spending concentrated in research and development rather than product sales. That leaves Cash Cows empty and forces the BCG view toward a cash-burning growth stage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 recurring royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences had no meaningful recurring royalty stream by end-2025, so this was not a classic BCG cash cow. Any cash tied to partnerships likely came from upfront payments, milestones, or cost-sharing, not steady royalty income. That matters because recurring royalties usually fund low-growth businesses with predictable cash flow, and Precision BioSciences lacked that base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaboration fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. gets collaboration fees from Servier, iECURE, and other partners, which can bring upfront cash and milestone payments. That helps fund R\u0026amp;D and operations without commercial product sales, but these inflows are still partnership-linked and not a durable BCG cash cow. In 2025, this kind of revenue remains episodic, not recurring.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront fees support cash burn.\u003c\/li\u003e\n\u003cli\u003eMilestones can spike, then fade.\u003c\/li\u003e\n\u003cli\u003eNot stable enough for cash cow status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-dilutive funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. has relied on partnership economics, not mature operating cash flow, to fund this cash cow bucket. Research collaboration receipts and other non-dilutive support help extend runway, but they do not show the steady, self-funding cash generation of a true Cash Cow. \u003c\/p\u003e\n\u003cp\u003eSo this is a liquidity buffer, not a stable franchise. The mix lowers dilution risk, yet cash still depends on deal flow and milestone timing rather than repeatable operating surplus.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eResearch deals fund R\u0026amp;D and runway.\u003c\/li\u003e\n\u003cli\u003eNot a durable operating cash source.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Lacks a Cash Cow in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. had no Cash Cow in FY2025: 0 approved products, 0 marketed therapies, and no steady royalty stream. Cash came from collaboration fees, milestones, and cost-sharing, so inflows stayed episodic rather than recurring. This is a runway buffer, not a mature cash-generating franchise.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed therapies\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash cow status\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePrecision BioSciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview you see for the Precision BioSciences, Inc. BCG Matrix is the exact same document you’ll receive after purchase. There are no hidden changes, demo pages, or watermarks—just the full, ready-to-use file. Download it instantly and use it for strategic analysis, presentations, or planning with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCAR0191\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBCAR0191 is an allogeneic anti-CD19 CAR T candidate in Phase 1\/2a, so it remains an early-stage asset with no approved product sales. The CD19 market is already crowded, led by commercial products like Novartis' Kymriah and Gilead\/Kite's Yescarta, which makes share capture hard. With no commercial share by end-2025, PBCAR0191 fits the Dogs bucket: low share, low near-term cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCAR269A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBCAR269A is an investigational BCMA-targeting allogeneic CAR T for multiple myeloma, so it sits in a crowded field led by approved drugs like Bristol Myers Squibb's Abecma and Johnson \u0026amp; Johnson's Carvykti. Those two BCMA therapies already have major commercial traction, with 2024 sales of about $327 million and $963 million, which raises the bar for differentiation and market share. For Precision BioSciences, Inc., this makes PBCAR269A a Dogs asset in the BCG Matrix until clear clinical or commercial proof emerges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCAR19B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBCAR19B fits the Dogs box in Precision BioSciences, Inc.'s BCG Matrix: it is a single-step gene-edit stealth-cell anti-CD19 CAR T concept, but it stayed development-stage through end-2025, with no commercial sales to build share. Early differentiation is real, yet without late-stage data, approvals, or revenue, it does not move the profit pool. Precision BioSciences also remained R\u0026amp;D-led, so this asset looked like a cash user, not a market winner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCD19 crowding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCD19 crowding is a clear Dog for Precision BioSciences, Inc.: the CD19 CAR-T field is already packed with approved leaders like Kite Pharma’s Yescarta and Novartis’s Kymriah, plus many pipeline rivals. Precision BioSciences, Inc.’s allogeneic model faces heavier competition, so near-term share leadership looks unlikely.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCD19 CAR-T is already crowded\u003c\/li\u003e\n\u003cli\u003eBig incumbents have approved products\u003c\/li\u003e\n\u003cli\u003eAllogeneic approach is harder to win\u003c\/li\u003e\n\u003cli\u003eNear-term market share upside is weak\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy ex vivo CAR T\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. legacy ex vivo CAR T assets have not reached commercialization, so in BCG terms they fit the Dog bucket: low market share, weak near-term payoff, and ongoing cash use in a crowded oncology field.\u003c\/p\u003e\n\u003cp\u003eWith no late-stage product sales from this older program line, these assets look more like capital drains than growth engines, especially versus 2025\/2026 priorities in gene editing and next-gen cell therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrecommercial\u003c\/li\u003e\n\u003cli\u003eCrowded oncology market\u003c\/li\u003e\n\u003cli\u003eCapital use without strong returns\u003c\/li\u003e\n\u003cli\u003eMost dog-like portfolio segment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences' Dog Assets Face Crowded CAR-T Rivals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc.'s Dog assets stay precommercial through 2025, with no approved sales and weak share in crowded CD19 and BCMA spaces. PBCAR0191 and PBCAR269A face entrenched rivals like Yescarta, Kymriah, Abecma, and Carvykti, so near-term upside is limited. These programs look like cash users, not BCG winners.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBCAR0191\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2a\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBCAR269A\u003c\/td\u003e\n\u003ctd\u003ePrecommercial\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBGENE-DMD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBGENE-DMD fits the Question Marks box in Precision BioSciences, Inc.’s BCG mix: Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 live male births, so the addressable need is large, but PBGENE-DMD is still pre-commercial and had no market share by end-2025. As an ARCUS-based gene-editing program, it has high upside if clinical data land well, but it also carries high execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHBV curative editing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChronic hepatitis B affects about 254 million people worldwide and causes roughly 1.1 million deaths a year, so the market need is huge. PBGENE-HBV is still early and has not yet shown clear clinical or commercial traction, while Precision BioSciences, Inc. reported no product revenue in 2025. That makes HBV curative editing a classic question mark: big upside, but unproven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid tumor CAR T\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. and Servier have discussed expanding CAR T beyond CD19, and that keeps solid tumors in the question-mark bucket. Solid tumors make up about 90% of cancers, so the prize is huge, but allogeneic CAR T still has not shown clear dominance there. As of 2026, Precision BioSciences, Inc. still has minimal share in this frontier, so the upside is real but unproven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eARCUS expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eARCUS can be extended into multiple new therapeutic uses, so Precision BioSciences, Inc. has real upside if the platform keeps proving itself. But these programs stay \"question marks\" until more clinical readouts and partner wins show clear demand in a gene-editing market that is still expanding in 2025\/2026.\u003c\/p\u003e\n\u003cp\u003eThat means the value is mostly in optionality today, not cash flow. One clean signal from a larger Phase 2\/3 data set or a new license deal could move ARCUS from a BCG question mark toward a stronger growth asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad platform, but limited proof\u003c\/li\u003e\n\u003cli\u003eMore indications can lift value\u003c\/li\u003e\n\u003cli\u003eClinical data is the key gate\u003c\/li\u003e\n\u003cli\u003ePartner adoption will shape scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew partnered programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew partnered programs like iECURE and Servier could become Precision BioSciences, Inc. growth shots if expansion data keeps improving. External partners cut cash burn and can speed development, which matters in a biotech market that reached about $1.55 trillion in 2024. Still, these programs stay in the Question Mark bucket until they show stronger clinical and regulatory proof.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnered programs lower funding pressure.\u003c\/li\u003e\n\u003cli\u003eNew targets can add upside fast.\u003c\/li\u003e\n\u003cli\u003eData readouts decide star potential.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences: High Upside, Zero Revenue—All Eyes on Clinical Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. keeps its Question Marks in early-stage, high-upside assets: PBGENE-DMD, PBGENE-HBV, and partnered ARCUS programs. None had 2025 product revenue, so value still depends on clinical proof, not cash flow. The upside is real, but so is failure risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGENE-DMD\u003c\/td\u003e\n\u003ctd\u003ePre-commercial\u003c\/td\u003e\n\u003ctd\u003e0 share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGENE-HBV\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003e0 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234294374665,"sku":"dtil-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/dtil-bcg-matrix.webp?v=1785717166","url":"https:\/\/dcfanalyst.com\/products\/dtil-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}